drugset / Trial / NCT00986778
Entecavir Plus Adefovir in Lamivudine-Resistant Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
Combination therapy with entecavir 1.0 mg plus adefovir 10 mg has superior antiviral activity compared with either entecavir monotherapy 1.0 mg or adefovir 10 mg plus lamivudine 100 mg in Chinese adults with lamivudine-resistant chronic hepatitis B infection
Timeline
- Start
- 2009-12
- Primary completion
- 2012-12
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adefovir | Unknown | 10 mg | Oral |
| Subject | Entecavir | Small molecule | 1 mg | Oral |
| Comparator | Lamivudine | Other / unclassified | 100 mg | Oral |